Clinical utility of intralesional methotrexate to distinguish crateriform keratinocytic tumors before surgery

Published: 14 September 2020| Version 1 | DOI: 10.17632/dwd6xx6gvy.1
Rafael Salido-Vallejo


Mendeley supplemental figure 1. Crateriform tumors with similar size and location before and after intralesional methotrexate administration. Keratoacanthoma tumors (A and C) underwent a marked reduction in size compared with cutaneous squamous cell carcinoma (B and D).